Delivery Order 36F79719D0153-36C26020F0130
Award Date
12/19/19
Potential Completion Date
3/17/20
Potential Value
$18K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Genzyme Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $204,743.40 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) prime vendor contract vehicle. The order calls for the delivery of the drug eliglustat to the Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 in Cambridge, Massachusetts by February 25, 2021. No set-aside designation was applied to...
Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $17,830.87 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The firm fixed price order is for the provision of eliglustat to the agency's Cambridge, Massachusetts facility, with an anticipated completion date of April 19,...
This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Genzyme Corporation, a division of Sanofi Genzyme, to provide the drug eliglustat for the VA's Puget Sound healthcare network. The order was placed against Genzyme's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA, which has a potential value of $660 million over 5 years. This delivery order is valued at $106,985.22 and has a completion date of March...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $212,340.40 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to Genzyme Corporation for the bulk purchase of 84mg oral capsules of Eliqlustat (Cerdelga). Performance will take place in Cambridge, Massachusetts with no set-aside designation applied. Genzyme Therapeutics Division, doing business as Sanofi Genzyme, will serve as the...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $265,045.04 firm fixed price delivery order to Genzyme Corporation, doing business under its Genzyme Therapeutics Division, for eliglustat medication. The period of performance is from October 1, 2020 to September 30, 2021. The delivery order was awarded against Genzyme Corporation's Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21 (VISN 21) to Genzyme Corporation, doing business as Sanofi Genzyme, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The $89,094.00 order is for the delivery of various specialty pharmaceutical products, including Eliglustat (Cerdelga), Lemtrada, and Caprelsa (vandetanib), to support treatment programs for veterans. Genzyme...
This federal contract award is for the delivery of Eliglustat (Cerdelga) 84mg oral capsules to the Puget Sound VA Health Care System. The $144,553.36 firm fixed price delivery order was issued against Genzyme Corporation's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) with the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). Genzyme Corporation, doing business as Sanofi Genzyme, is the prime contractor for this order, with no set-aside designation...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $17,830.87 delivery order to Genzyme Corporation, Sanofi Genzyme division, for eliglustat for the Puget Sound VA pharmacy. The contract was issued against the Pharmaceuticals and Drugs Federal Supply Schedule, known as FSS-61-IB, with a firm fixed price and completion date of November 1, 2019. The delivery order was not subject to any set-aside designations and will provide the...
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order contract to Genzyme Corporation, a division of Sanofi Genzyme, to provide the drug CERDELGA. The contract has a potential value of $106,912.80 and a completion date of March 31, 2019. Genzyme is the prime contractor on this award, which was placed against the company's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a multiple award schedule managed by the VA. The...
Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics division, was awarded a $81,714.85 firm fixed price delivery order against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1. The contract calls for the delivery of LEMTRADA MED to Cambridge, MA by August 30, 2020. The award utilizes the Pharmaceuticals and Drugs GSA Schedule, a multiple award...